

ASX Announcement

Darren Keamy appointed Chief Financial Officer and Company Secretary

- Mr Keamy brings almost two decades experience as CFO & Company Secretary at ASX-listed multinational biotech success story Clinuvel Pharmaceuticals Ltd
- Expertise spanning corporate governance, risk management, international expansion, financial reporting & capital raising

Sydney, Australia, 4 March 2025: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce the appointment of Darren Keamy as the Company's Chief Financial Officer (CFO) and Company Secretary starting today.

Mr Keamy is an experienced finance executive with a career spanning over 25 years in corporate finance, financial strategy, and investor relations within the biopharmaceutical industry. Prior to joining Imugene, he served as Chief Financial Officer and Company Secretary at Clinuvel Pharmaceuticals Ltd from 2005 to 2024, where he played a pivotal role in the company's transformation from a small biotech start-up to a cash generating, profitable, multinational, ASX-listed organisation.

During his tenure at Clinuvel, Mr Keamy was instrumental in capital raising efforts, securing over \$95 million through various funding mechanisms as the company graduated from a market capitalisation of approximately \$60 million to a high point of more than \$2.1 billion.

His expertise extends across corporate governance, risk management, financial reporting, and international expansion, having established legal and operational frameworks in multiple jurisdictions including the US, Switzerland, Singapore, Ireland, Monaco, and the UK. His commercial acumen has been pivotal in optimising financial strategies, enhancing operational efficiencies, and navigating complex regulatory environments.

Before joining Clinuvel, Mr Keamy held various financial leadership roles within global packaging specialists Amcor Limited, as well as Salomon Smith Barney (now part of Citigroup) and Superdrug Stores Plc in the UK. His extensive experience across finance, risk management, and compliance has equipped him with a deep understanding of complex financial structures and international business operations.



Mr Keamy holds a Bachelor of Commerce (Accounting) from La Trobe University, is a Certified Practising Accountant (CPA), and qualified Company Secretary having obtained a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.

Imugene's Managing Director and Chief Executive Officer, Leslie Chong, said:

“Darren’s outstanding experience in financial management, capital markets, and corporate governance within the life sciences sector makes him a valuable addition to Imugene. His proven ability to drive financial performance and strategic growth will support the company as we continue advancing our immuno-oncology pipeline. We are delighted to have him on board.”

Mr Keamy replaces Mike Tonroe, who is resigning from his position as CFO and Company Secretary. The Board and management of Imugene would like to thank Mr Tonroe for his service and contributions to the Company and wish him all the best in his future endeavours.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.